Over two and a half centuries, the U.S. has transformed from a young nation wary of corporations to the world’s most complex and influential capital market. And with that evolution came a parallel rise in the systems designed to keep corporations honest.
Artificial intelligence has become the centerpiece of corporate strategy across nearly every sector. But as companies race to position themselves as “AI‑driven,” regulators are increasingly concerned that some claims are exaggerated, misleading, or unsupported.
FDA warning letters are sending a clear message: promotional claims that exaggerate benefits or hide risks won’t go unchecked. Recent actions against major drugmakers and digital advertisers show how quickly misleading statements can escalate into regulatory scrutiny, market fallout, and investor exposure.
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2026 – Robbins LLP
Protect yourStock Watch members receive free investment monitoring and notifications.
Protect yourStock Watch members receive free investment monitoring and notifications.
